sMVA-S
A viral vector SARS-CoV-2 candidate vaccine.
General information
sMVA-S is a vaccinia virus vector-based experimental vaccine assembled using synthetic DNA constructs into which SARS-CoV-2 Spike immunogen sequence(s) were introduced (Chiuppesi et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
Spike protein Nucleocapsid protein Viral vector Animal model In vitro Mixed substance |
BHK cells; HeLa cells; BALB/c mice; C57BL/6 mice; C57BL/6 mice expressing the human leukocyte antigen | 12.12 | Induced immunogen synthesis in cell culture. Immunization of mice led to anti-immunogen high-titre antibody production (higher levels than those in sera of convalescent patients). Antibody-dependent enhancement was not observed. Anti-RBD (of SARS-CoV-2 Spike protein) antibody response was observed, as well. The elicited Spike antigen neutralization antibody response was potent against both SARS-CoV-2 live and pseudotyped viruses. Strong CD8+ and CD4+ T-cell responses were detected. |
Nov/30/2020 |
